Open an account

PURE Biosciences

PURE · OTC

$0.072+$0.0059 (+8.93%)TodayMarket closed ·
Prev close $0.0661

About PURE

PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. The company is headquartered in El Cajon, California and currently employs 11 full-time employees. The firm is focused on developing and commercializing its proprietary antimicrobial products, primarily in the food and beverage industry. The company provides solutions to combat the health and environmental challenges of pathogens and hygienic control. Its technology platform is based on patented, stabilized ionic silver, and its initial products contain SDC. Its registered offerings include PURE Hard Surface, a food contact surface sanitizer and disinfectant designed for restaurant chains, food processors, and transportation companies, as well as PURE Control, a direct food contact processing aid. The company also supplies SDC-based formulations as raw material ingredients for personal care products. Its SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency, the United States Food and Drug Administration, and Health Canada.

Employees
11
Headquarters
El Cajon, California
Listed
Aug 8, 1996
Sector
Consumer Staples
Industry
Household Products
Website
purebio.com

PURE key statistics

Market cap
9.36M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
23.91K
Volume
20.65K
Open price
$0.07
High today
$0.0802
Low today
$0.0691
52 Week high
$0.0999
52 Week low
$0.0386

PURE Biosciences (PURE) at a glance

As of Oct 20, 2026, PURE Biosciences (PURE) shares are priced at $0.072, giving the company a market cap of 9.36M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0691 and $0.0802. The current price is 4.2% above the day's low and 10.2% below its high.

Volume so far is 20.65K shares, in line with the average of 23.91K shares a day.

Over the past year PURE Biosciences has ranged from $0.0386 to $0.0999, and now sits 54% of the way up that range.

PURE Biosciences met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q1 FY26 it reported $0.00 per share against an estimate of $0.00.

PURE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 19.9% on average.

  1. Q4 FY07: reported -$0.64 per share against an estimate of -$0.3264
  2. Q1 FY08: reported -$0.32 per share against an estimate of -$0.408
  3. Q2 FY08: reported -$0.48 per share against an estimate of -$0.408
  4. Q3 FY11: reported -$0.40 per share against an estimate of -$0.4896
  5. Q4 FY11: reported -$0.40 per share against an estimate of -$0.3264
  6. Q1 FY12: reported -$0.48 per share against an estimate of -$0.2448
  7. Q1 FY24: reported -$0.01 per share against an estimate of $0.00
  8. Q1 FY26: reported $0.00 per share against an estimate of $0.00

PURE news

  • Press releaseBusiness Wire

    PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    PURE Bioscience, Inc. Announces Leadership Promotions

  • Press releaseBusiness Wire

    PURE Bioscience Reports Fiscal 2025 Financial Results

  • Press releaseBusiness Wire

    PURE Bioscience Partners with Bonsai for Direct-to-Customer Sales

  • Press releaseBusiness Wire

    PURE Bioscience Reports Fiscal Third Quarter 2025 Financial Results

  • Press releaseBusiness Wire

    PURE Bioscience Unveils Revolutionary Membrane Treatment Solution for the Dairy and Beverage Industry

Similar companies

Companies in the same industry as PURE Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.